2023 World Conference on Lung Cancer (Posters)-EP13.07. Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients

EP13.07. Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients - PDF(Slides)

Pdf Summary

In this study, researchers examined the efficacy of platinum-based therapy given after treatment with lurbinectedin in patients with platinum-sensitive relapsed small-cell lung cancer (SCLC). The baseline characteristics of the patient groups were similar, and no relevant differences were observed in various factors such as median CTFI, response to prior platinum, bulky disease, or lactate dehydrogenase values.<br /><br />The efficacy results, assessed by an Independent Review Committee (IRC), showed that treatment with lurbinectedin resulted in a comparable overall response rate (ORR) in both groups (48.1% vs. 47.1%), but patients who received further platinum had a longer median overall survival (OS) of 15.9 months compared to 11.8 months in those who did not receive further platinum.<br /><br />Lurbinectedin was approved for the treatment of metastatic SCLC with disease progression after platinum-based chemotherapy. The study included 105 patients who received lurbinectedin, of which 60 had a chemotherapy-free interval (CTFI) of more than 90 days. Among these patients, 44 received further systemic therapy after disease progression, with 27 receiving platinum-based chemotherapy.<br /><br />The results showed that patients who received platinum as immediate therapy after lurbinectedin had an ORR of 35.3%, a median progression-free survival (PFS) of 3.4 months, and a median OS of 7.2 months.<br /><br />Overall, the study suggests that lurbinectedin is a valuable therapeutic alternative for second-line platinum-sensitive relapsed SCLC patients. It may effectively extend the platinum-free interval while maintaining the possibility of third-line platinum-based therapy, which could lead to improved outcomes. However, the study has limitations due to its small sample size.

Asset Subtitle

Jose Manuel Trigo

Meta Tag

Speaker Jose Manuel Trigo

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

platinum-based therapy

lurbinectedin

small-cell lung cancer

SCLC

relapsed

efficacy

overall response rate

overall survival

chemotherapy-free interval

progression-free survival